What's Next In Vaccines (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline)

Date: June 5, 2012
Pages: 215
Price:
US$ 3,995.00
License [?]:
Publisher: Kalorama Information
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H2F084F4C95EN
Leaflet:

Download PDF Leaflet

What's Next In Vaccines (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline)
Vaccines are one of the most dynamic parts of the pharmaceutical business today but future growth will depend on a considerable amount of potential vaccines in the pipeline.This Kalorama Information report What's Next in Vaccines? examines and estimates the market for vaccines that have yet to be launched. What diseases may see a prophylactics vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can current vaccine success stories tell us about the future of the vaccine market? The following target areas are covered in the report:
  • Acne
  • Addiction
  • Allergy
  • Alzheimer’s Disease
  • Anthrax
  • Asthma
  • Campylobacter Infection
  • Chlamydia
  • Croup
  • Cytomegalovirus (CMV)
  • Dengue Fever
  • Diabetes
  • Ebola
  • Epstein-Barr Virus
  • Enterotoxigenic Escherichia coli (ETEC)
  • Heart Attack
  • Helicobacter Pylori
  • Hepatitis
  • Herpesvirus
  • Hookworm
  • Hypertension
  • HIV/AIDS
  • Leishmaniasis
  • Malaria
  • MRSA Infection
  • Multiple Sclerosis
  • Obesity
  • Parainfluenza Virus Type 3
  • Parkinson’s Disease
  • Plague
  • Ross River Virus
  • Shigellosis
  • Stroke
  • Tuberculosis
  • West Nile Virus

For each of these areas the report provides Mortality, Severity and Treatment Availability ratings. For marketers and industry watchers a knowledge of all of the potential vaccines will be important to understand how pharma is seeking to renew bottom line with aggressive prophylactic strategies, and who the winners and losers in the near future may be. Kalorama Information has looked at the vaccine market three times in as many years for Kalorama Information, and in this report applies a knowledge of what companies have done in the past to potential efforts.



There are a number of trends that will impact the industry that market watchers will want to know about, and Kalorama Information has covered these trends; including: New Vaccine Technologies, DNA Vaccination, Recent Project Terminations, Innovative Delivery Systems, Edible Vaccines, Vaccine Patches, Funding Shortfalls. The report also discusses vaccine manufacturing methods and the approval process. In addition, the report focuses on the emerging vaccine activities of the following companies


  • Affiris
  • Alk-Abello A/S
  • Allergy Therapeutics
  • AstraZeneca
  • Bavarian Nordic A/S
  • Baxter Healthcare
  • Crucell
  • Cytos Biotechnology
  • GlaxoSmithKline
  • Hawaii Biotech
  • Merck & Co. Inc
  • Mymetics
  • Nabi Biopharmaceuticals
  • Novartis
  • Opexa Therapeutics
  • Sanofi Pasteur

This report provides forecasted revenues for products in development out to 2021. The report does not does not cover indication expansions of existing vaccine products, nor does it cover vaccines for which products currently exist and are widely available, but may need improvement. Development of vaccines that incorporate new production methods (such as the migration of chicken eggs to mammal, yeast or other cells) is also excluded. Cancer vaccines are excluded as Kalorama has an entire report on this topic.
Sales estimates for each market segment represent global revenues and are expressed in current dollars. Information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources.
CHAPTER ONE: EXECUTIVE SUMMARY

Emerging Vaccines
  Scope and Methodology
  Overview
  Emerging Vaccines and Forecasts
  The Global Market for Emerging Vaccines

CHAPTER TWO: INTRODUCTION TO VACCINES

A Brief History: The Development of Vaccines
The Immune Response
Mechanism of Action
Types of Vaccines
  Attenuated (Weakened) Live Viruses
  Killed (Inactivated) Viruses
  Toxoid Vaccines
  Genetically Engineered/Modified Vaccines
  Bacteria-Based Vaccines
Vaccine Approval Process
Refusal to Immunize
Expanding Vaccine Availability
Other Trends Driving the Vaccines Market

CHAPTER THREE: EMERGING VACCINES

Introduction
Emerging Vaccines by Disease Area
  Acne
  Addiction
  Allergy
  Alzheimer’s Disease
  Anthrax
  Asthma
  Campylobacter Infection
  Chlamydia
  Croup
  Cytomegalovirus (CMV)
  Dengue Fever
  Diabetes
  Ebola
  Epstein-Barr Virus
  Enterotoxigenic Escherichia coli (ETEC
  Heart Attack
  Helicobacter Pylori
  Hepatitis
  Herpesvirus
  Hookworm
  Hypertension

  HIV/AIDS

  Leishmaniasis
  Malaria
  MRSA Infection
  Multiple Sclerosis
  Obesity
  Parainfluenza Virus Type 3
  Parkinson’s Disease
  Plague
  Ross River Virus
  Shigellosis
  Stroke
  Tuberculosis
  West Nile Virus

CHAPTER FOUR: EMERGING VACCINES MARKET FORECAST

the Global Market for Emerging Vaccines
Emerging Vaccines Market Segment Forecasts
  Acne
  Addiction
  Allergies
  Alzheimer’s Disease
  Anthrax
  Asthma
  Campylobacter Infection
  Celiac Disease
  Chlamydia
  Croup
  Diabetes
  Ebola
  EBV Infection
  ETEC Infection
  Heart Attack
  H. Pylori Infection
  Hepatitis C and E
  Herpesvirus Infection
  Hookworm
  Hypertension

  HIV/AIDS

  Leishmaniasis
  Malaria
  MRSA Infection
  Multiple Sclerosis
  Obesity
  PIV-3 Infection
  Parkinson’s Disease
  Plague
  RSV Infection
  Ross River Virus Infection
  Shigellosis
  Stroke
  Tuberculosis
  West Nile Virus

CHAPTER FIVE: ISSUES AND TRENDS

New Vaccine Delivery System
  Edible Vaccines
  Mucosal Delivery
  Intranasal Delivery
  Vaccine Patches
Funding Shortfalls
Project Terminations

CHAPTER SIX: COMPANY PROFILES

Affiris
  History and Lines of Business
  Emerging Vaccine Activities
  Financial Information
Alk-Abello A/S
  History and Lines of Business
  Emerging Vaccine Activities
  Financial Information
Allergy Therapeutics
  History and Lines of Business
  Emerging Vaccine Activities
  Financial Information
AstraZeneca
  History and Lines of Business
  Emerging Vaccine Products
  Financial Information
Bavarian Nordic A/S
  History and Lines of Business
  Emerging Vaccine Activities
  Financial Information
Baxter Healthcare
  History and Lines of Business
  Emerging Vaccine Activities
  Financial Information
Crucell
  History and Lines of Business
  Emerging Vaccine Activities
  Financial Information
Cytos Biotechnology
  History and Lines of Business
  Emerging Vaccine Activities
  Financial
GlaxoSmithKline
  History and Lines of Business
  Emerging Vaccine Activities
  Financial Information
Hawaii Biotech
  History and Lines of Business
  Emerging Vaccine Products
  Financial Information
Merck & Co. Inc
  History and Lines of Business
  Emerging Vaccine Activities
  Financial Information
Mymetics
  History and Lines of Business
  Emerging Vaccine Products
  Financial Information
Nabi Biopharmaceuticals
  History and Lines of Business
  Emerging Vaccine Activities
  Financial Information
Novartis
  History and Lines of Business
  Emerging Vaccine Activities
  Financial Information
Opexa Therapeutics
  History and Lines of Business
  Emerging Vaccine Activities
  Financial Information
Sanofi Pasteur
  History and Lines of Business
  Emerging Vaccine Activities
  Financial Information

APPENDIX: COMPANY DIRECTORY

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1: Status of Emerging Vaccines by Disease

CHAPTER TWO: INTRODUCTION TO VACCINES

Table 2-1: Impact of Vaccines in the 20th Century Annual Morbidity in the 20th Century vs 2011
Table 2-2: Vaccine-Preventable Diseases, December 2011
Figure 2-1: Attenuated Virus Production
Table 2-3: VAERS Table of Reportable Events Following Vaccination

CHAPTER THREE: EMERGING VACCINES

Figure 3-1: Global Prevalence of Conditions Addressed by Emerging Vaccines, 2012
Figure 3-2: Comparative Mortality, Symptom Severity and Treatment Availability for Conditions Addressed by Emerging Vaccines
Table 3-1: Emerging Vaccines by Disease and Stage of Testing
Figure 3-3: Comparative Severity Ranking of Acne
Figure 3-4: Comparative Severity Ranking of Addiction
Figure 3-5: Comparative Severity Ranking of Allergy
Figure 3-6: Comparative Severity Ranking of Alzheimer’s Disease
Figure 3-7: Comparative Severity Ranking of Anthrax
Figure 3-8: Comparative Severity Ranking of Asthma
Figure 3-9: Comparative Severity Ranking of Campylobacter Infection
Figure 3-10: Comparative Severity Ranking of Celiac Disease
Figure 3-11: Comparative Severity Ranking of Chlamydia
Figure 3-12: Comparative Severity Ranking of Croup
Figure 3-13: Comparative Severity Ranking of Cytomegalovirus
Figure 3-14: Comparative Severity Ranking of Dengue Fever
Figure 3-15: Comparative Severity Ranking of Diabetes
Figure 3-16: Comparative Severity Ranking of Ebola
Figure 3-17: Comparative Severity Ranking of EBV
Figure 3-18: Comparative Severity Ranking of ETEC
Figure 3-19: Comparative Severity Ranking of Heart Attack
Figure 3-20: Comparative Severity Ranking of H. Pylori Infection
Figure 3-21: Comparative Severity Ranking of Hepatitis C and E
Figure 3-22: Comparative Severity Ranking of Herpesvirus Infection
Figure 3-23: Comparative Severity Ranking of Hookworm
Figure 3-24Comparative Severity Ranking of Hypertension
Figure 3-25: Comparative Severity Ranking of HIV/AIDS
Figure 3-26: Comparative Severity Ranking of Leishmaniasis
Figure 3-27: Comparative Severity Ranking of Malaria
Figure 3-28: Comparative Severity Ranking of MRSA Infection
Figure 3-29: Comparative Severity Ranking of Multiple Sclerosis
Figure 3-30: Comparative Severity Ranking of Obesity
Figure 3-31: Comparative Severity Ranking of PIV-3 Infection
Figure 3-32: Comparative Severity Ranking of Parkinson’s Disease
Figure 3-33: Comparative Severity Ranking of Plague
Figure 3-34: Comparative Severity Ranking of RSV Infection
Figure 3-35: Comparative Severity Ranking of Ross River Virus Infection
Figure 3-36: Comparative Severity Ranking of Shigellosis
Figure 3-37: Comparative Severity Ranking of Stroke
Figure 3-38: Comparative Severity Ranking of Tuberculosis
Figure 3-39: Comparative Severity Ranking of West Nile Virus Infection

CHAPTER FOUR: MARKET ANALYSIS

Table 4-1:World Market for Emerging Vaccines by Type, 2011
Table 4-2: World Market for Emerging Vaccines by Type, 2011-2021
Table 4-3: World Acne Vaccine Market 2011-2021
Table 4-4: World Addiction Vaccine Market 2011-2021
Table 4-5: World Allergy Vaccine Market 2011-2021
Table 4-6: World Alzheimer’s Disease Vaccine Market 2011-2021
Table 4-7: World Anthrax Vaccine Market 2011-2021
Table 4-8: World Asthma Vaccine Market 2011-2021
Table 4-9: World Campylobacter Vaccine Market 2011-2021
Table 4-10: World Celiac Disease Vaccine Market 2011-2021
Table 4-11: World Chlamydia Vaccine Market 2011-2021
Table 4-12: World Croup Vaccine Market 2011-2021
Table 4-13: World Cytomegalovirus Vaccine Market 2011-2021
Table 4-14: World Dengue Fever Vaccine Market 2011-2021
Table 4-15: World Diabetes Vaccine Market 2011-2021
Table 4-16: World Ebola Vaccine Market 2011-2021
Table 4-17: World EBV Vaccine Market 2011-2021
Table 4-18: World ETEC Vaccine Market 2011-2021
Table 4-19: World Heart Attack Vaccine Market 2011-2021
Table 4-20: World H. Pylori Vaccine Market 2011-2021
Table 4-21: World Hepatitis C & E Vaccine Market 2011-2021
Table 4-22: World Herpesvirus Vaccine Market 2011-2021
Table 4-23: World Hookworm Vaccine Market 2011-2021
Table 4-24: World Hypertension Vaccine Market 2011-2021
Table 4-25: World HIV/AIDS Vaccine Market 2011-2021
Table 4-26: World Leishmaniasis Vaccine Market 2011-2021
Table 4-27: World Malaria Vaccine Market 2011-2021
Table 4-28: World MRSA Vaccine Market 2011-2021
Table 4-29: World Multiple Sclerosis Vaccine Market 2011-2021
Table 4-30: World Obesity Vaccine Market 2011-2021
Table 4-31: World PIV-3 Vaccine Market 2011-2021
Table 4-32: World Parkinson’s Disease Vaccine Market 2011-2021
Table 4-33: World Plague Vaccine Market 2011-2021
Table 4-34: World RSV Vaccine Market 2011-2021
Table 4-35: World Ross River Virus Vaccine Market 2011-2021
Table 4-36: World Shigellosis Vaccine Market 2011-2021
Table 4-37: World Stroke Vaccine Market 2011-2021
Table 4-38: World Tuberculosis Vaccine Market 2011-2021
Table 4-39: World West Nile Virus Vaccine Market 2011-2021
Skip to top


Ask Your Question

What's Next In Vaccines (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline)
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: